Is dyslipidaemia important if we control glycaemia?

Area of Science:

• Endocrinology
• Cardiology
• Metabolic Syndrome

Background:

• Type 2 diabetes significantly increases morbidity and mortality from cardiovascular disease (CVD).
• Patients with type 2 diabetes exhibit a cluster of coronary heart disease (CHD) risk factors, including dyslipidemia.
• Standard intensive glucose-lowering interventions have failed to eliminate elevated cardiovascular risk.

Purpose of the Study:

• To evaluate the effectiveness of multifactorial interventions in reducing cardiovascular risk in type 2 diabetes.
• To explore strategies for improving high-density lipoprotein cholesterol (HDL-C) levels in this population.
• To identify safe and effective combination lipid-lowering therapies for type 2 diabetes and metabolic syndrome.

Main Methods:

• Review of studies on multifactorial interventions for cardiovascular risk reduction in type 2 diabetes.
• Analysis of the impact of statins and other lipid-modifying agents on CHD risk.
• Examination of the role of HDL-C and strategies to increase it.

Main Results:

• Multifactorial interventions, including statin therapy for lipid normalization, show greater efficacy in reducing CHD than single-factor approaches.
• Risk reduction in type 2 diabetes patients often mirrors that in non-diabetic individuals, despite higher baseline risk.
• Statins minimally improve HDL-C; additional interventions are needed, but combining fibrates with statins carries risks.

Conclusions:

• Multifactorial interventions are superior for managing cardiovascular risk in type 2 diabetes.
• Targeting HDL-C is crucial for further reducing cardiovascular morbidity and mortality.
• Novel combination lipid-normalizing therapies are required for patients with type 2 diabetes or metabolic syndrome, avoiding risks associated with current combinations.